Fractal Therapeutics makes model-based drug development more than just a set of buzzwords. In our hands, modeling underpins a practical cross-disciplinary approach to accelerating drug R&D. We engage on a target and modality-exclusive basis with early-stage partners on their programs, using our approaches to provide robust model-based answers to critical-path questions on the road to new asset creation and development. Our work couples mathematical modeling tightly with carefully designed animal studies and clinical trials. Fractal's model-based analyses and preclinical strategies help clients put together a more rigorous Investigational New Drug application and be more successful in early clinical development. Our team at Fractal is made up of drug developers who know how to use modeling to advance a drug quickly and efficiently. Taking an engineering approach, we frame questions in drug R&D in terms of quantitative analyses that can often be addressed with existing experimental data, allowing more progress for each unit of experimental effort.